Now showing items 1-5 of 5
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-03-20)
Background: Ovarian cancer early detection markers CA125, CA15.3, HE4, and CA72.4 vary between healthy women, limiting their utility for screening. <br>Methods: We evaluated cross-sectional relationships between lifestyle and reproductive factors and these markers among controls ( n = 1910) from a nested case-control study in the European Prospective Investigation into Cancer and Nutrition ...
Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-02-08)
Background:<br>Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.<br>Methods:<br>A case-control ...
Measured adiposity in relation to head and neck cancer risk in the European prospective investigation into cancer and nutrition.
(Journal article; Tidsskriftartikkel, 2017-06)
<b>Background</b>: Emerging evidence from cohort studies indicates that adiposity is associated with greater incidence of head and neck cancer. However, most studies have used self-reported anthropometry which is prone to error.<br><b>Methods</b>: Among 363,094 participants in the European Prospective Investigation into Cancer and Nutrition study (EPIC) with measured anthropometry, there were 837 ...
Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort.
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-31)
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has ...
Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: A nested case-control study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-04)
Background:<br>Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede the development of liver cancer. However, human studies, particularly from prospective settings, are lacking.<br>Methods:<br>We used a case-control study design nested within a large prospective cohort to assess the association between circulating levels of anti-lipopolysaccharide ...